Generic Drugs Market is expected to grow with a CAGR of 8% during the forecast period of 2018 to 2025.
CHAPTER 1. INTRODUCTION
1.1. RESEARCH METHODOLOGY
1.1.1. ERC DESK RESEARCH
1.1.2. ERC DATA SYNTHESIS
1.1.3. DATA VALIDATION AND MARKET FEEDBACK
1.1.4. ERC DATA SOURCES
CHAPTER 2. GENERIC DRUGS MARKET OVERVIEW
2.1. GENERIC DRUGS MARKET INTRODUCTION
2.2. GLOBAL GENERIC DRUGS MARKET PRODUCTION AND GROWTH RATE, 2017-2025
2.2.1. GLOBAL GENERIC DRUGS PRODUCTION (VOLUME) AND GROWTH RATE (%), (2017-2025)
2.3. GLOBAL GENERIC DRUGS MARKET CAPACITY AND GROWTH RATE, 2017-2025
2.3.1. GLOBAL GENERIC DRUGS CAPACITY (VOLUME) AND GROWTH RATE (%), (2017-2025)
2.4. GLOBAL GENERIC DRUGS MARKET REVENUE AND GROWTH RATE, 2017-2025
2.4.1. GLOBAL GENERIC DRUGS MARKET REVENUE (MILLION USD) AND GROWTH RATE (%), (2017-2025)
2.5. GLOBAL GENERIC DRUGS MARKET CONSUMPTION AND GROWTH RATE, 2017-2025
2.5.1. GLOBAL GENERIC DRUGS CONSUMPTION (VOLUME) AND GROWTH RATE (%), (2017-2025)
CHAPTER 3. GLOBAL GENERIC DRUGS MARKET BY BRAND, 2017-2025
3.1. PURE GENERIC DRUGS
3.2. BRANDED GENERIC DRUGS
3.3. GLOBAL GENERIC DRUGS MARKET REVENUE BY BRAND, 2017-2025
3.3.1. GLOBAL GENERIC DRUGS MARKET REVENUE (MILLION USD) AND SHARE (%) BY BRAND, 2017-2025
3.3.2. PURE GENERIC DRUGS MARKET REVENUE AND GROWTH RATE, 2017-2025
3.3.3. BRANDED GENERIC DRUGS MARKET REVENUE AND GROWTH RATE, 2017-2025
3.4. GLOBAL GENERIC DRUGS MARKET PRODUCTION BY BRAND, 2017-2025
3.4.1. GLOBAL GENERIC DRUGS MARKET PRODUCTION (VOLUME) AND SHARE (%) BY BRAND, 2017-2025
3.4.2. PURE GENERIC DRUGS MARKET PRODUCTION AND GROWTH RATE, 2017-2025
3.4.3. BRANDED GENERIC DRUGS MARKET PRODUCTION AND GROWTH RATE, 2017-2025
CHAPTER 4. GLOBAL GENERIC DRUGS MARKET BY THERAPEUTIC APPLICATION, 2017-2025
4.1. CENTRAL NERVOUS SYSTEM (CNS)
4.2. CARDIOVASCULAR
4.3. DERMATOLOGY
4.4. ONCOLOGY
4.5. RESPIRATORY
4.6. OTHERS
4.7. GLOBAL GENERIC DRUGS MARKET REVENUE BY THERAPEUTIC APPLICATION, 2017-2025
4.7.1. GLOBAL GENERIC DRUGS MARKET REVENUE (MILLION USD) AND SHARE (%) BY THERAPEUTIC APPLICATION, 2017-2025
4.7.2. CENTRAL NERVOUS SYSTEM (CNS) MARKET REVENUE AND GROWTH RATE, 2017-2025
4.7.3. CARDIOVASCULAR MARKET REVENUE AND GROWTH RATE, 2017-2025
4.7.4. DERMATOLOGY MARKET REVENUE AND GROWTH RATE, 2017-2025
4.8. GLOBAL GENERIC DRUGS MARKET CONSUMPTION BY THERAPEUTIC APPLICATION, 2017-2025
4.8.1. GLOBAL GENERIC DRUGS MARKET CONSUMPTION (VOLUME) AND SHARE (%) BY THERAPEUTIC APPLICATION, 2017-2025
4.8.2. CENTRAL NERVOUS SYSTEM (CNS) MARKET CONSUMPTION AND GROWTH RATE, 2017-2025
4.8.3. CARDIOVASCULAR MARKET CONSUMPTION AND GROWTH RATE, 2017-2025
4.8.4. DERMATOLOGY MARKET CONSUMPTION AND GROWTH RATE, 2017-2025
CHAPTER 5. GLOBAL GENERIC DRUGS MARKET BY REGION, 2017-2025
5.1. NORTH AMERICA
5.1.1. U.S.
5.1.2. CANADA
5.1.3. MEXICO
5.2. EUROPE
5.2.1. U.K.
5.2.2. FRANCE
5.2.3. GERMANY
5.2.4. ITALY
5.2.5. SPAIN
5.2.6. REST OF EUROPE
5.3. ASIA PACIFIC
5.3.1. CHINA
5.3.2. JAPAN
5.3.3. INDIA
5.3.4. KOREA
5.3.5. REST OF APAC
5.4. SOUTH AMERICA
5.4.1. BRAZIL
5.4.2. REST OF SOUTH AMERICA
5.5. REST OF THE WORLD
5.5.1. MIDDLE EAST
5.5.2. AFRICA
5.6. GLOBAL GENERIC DRUGS MARKET REVENUE BY REGION, 2017-2025
5.6.1. GLOBAL GENERIC DRUGS MARKET REVENUE (MILLION USD) AND SHARE (%) BY REGION, 2017-2025
5.6.2. NORTH AMERICA MARKET REVENUE AND GROWTH RATE, 2017-2025
5.6.3. EUROPE MARKET REVENUE AND GROWTH RATE, 2017-2025
5.6.4. ASIA PACIFIC MARKET REVENUE AND GROWTH RATE, 2017-2025
5.6.5. SOUTH AMERICA MARKET REVENUE AND GROWTH RATE, 2017-2025
5.6.6. REST OF THE WORLD MARKET REVENUE AND GROWTH RATE, 2017-2025
CHAPTER 6. GLOBAL GENERIC DRUGS MARKET PRODUCTION AND CONSUMPTION ANALYSIS BY REGION, 2017-2025
6.1. GLOBAL GENERIC DRUGS MARKET PRODUCTION ANALYSIS BY REGION, 2017-2025
6.1.1. GLOBAL GENERIC DRUGS MARKET PRODUCTION (VOLUME) AND SHARE (%) BY REGION, 2017-2025
6.1.2. GLOBAL GENERIC DRUGS MARKET CONSUMPTION (VOLUME) AND SHARE (%) BY REGION, 2017-2025
6.1.3. NORTH AMERICA MARKET PRODUCTION AND CONSUMPTION, 2017-2025
6.1.4. EUROPE MARKET PRODUCTION AND CONSUMPTION, 2017-2025
6.1.5. ASIA PACIFIC MARKET PRODUCTION AND CONSUMPTION, 2017-2025
6.1.6. SOUTH AMERICA MARKET PRODUCTION AND CONSUMPTION, 2017-2025
6.1.7. REST OF THE WORLD MARKET PRODUCTION AND CONSUMPTION, 2017-2025
CHAPTER 7. MARKET DETERMINANTS
7.1. MARKET DRIVERS
7.2. MARKET RESTRAINTS
7.3. MARKET OPPORTUNITIES
7.4. MARKET DETERMINANTS RADAR CHART
CHAPTER 8. GLOBAL GENERIC DRUGS MARKET COMPETITION BY MANUFACTURERS
8.1. GLOBAL GENERIC DRUGS PRODUCTION AND SHARE BY MANUFACTURERS (2017-2025)
8.1.1. GLOBAL GENERIC DRUGS PRODUCTION (VOLUME) AND SHARE (%) BY MANUFACTURERS (2017-2025)
8.2. GLOBAL GENERIC DRUGS REVENUE AND SHARE BY MANUFACTURERS (2017-2025)
8.2.1. GLOBAL GENERIC DRUGS REVENUE (MILLION USD) AND SHARE (%) BY MANUFACTURERS (2017-2025)
8.3. GENERIC DRUGS MARKET COMPETITIVE SITUATION AND TRENDS
8.3.1. GENERIC DRUGS MARKET SHARE (%) OF TOP 3 MANUFACTURERS
8.3.2. GENERIC DRUGS MARKET SHARE (%) OF TOP 5 MANUFACTURERS
CHAPTER 9. GLOBAL GENERIC DRUGS MANUFACTURERS ANALYSIS
9.1. RANBAXY LABORATORIES, LTD
9.1.1. BUSINESS OVERVIEW
9.1.2. COMPANY BASIC INFORMATION
9.1.3. GENERIC DRUGS PRODUCT DETAILS
9.1.4. RANBAXY LABORATORIES, LTD GENERIC DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
9.2. ACTAVIS
9.2.1. BUSINESS OVERVIEW
9.2.2. COMPANY BASIC INFORMATION
9.2.3. GENERIC DRUGS PRODUCT DETAILS
9.2.4. ACTAVIS GENERIC DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
9.3. MYLAN, INC.
9.3.1. BUSINESS OVERVIEW
9.3.2. COMPANY BASIC INFORMATION
9.3.3. GENERIC DRUGS PRODUCT DETAILS
9.3.4. MYLAN, INC. GENERIC DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
9.4. TEVA PHARMACEUTICAL INDUSTRIES, LTD.
9.4.1. BUSINESS OVERVIEW
9.4.2. COMPANY BASIC INFORMATION
9.4.3. GENERIC DRUGS PRODUCT DETAILS
9.4.4. TEVA PHARMACEUTICAL INDUSTRIES, LTD. GENERIC DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
9.5. SANDOZ INTERNATIONAL GMBH
9.5.1. BUSINESS OVERVIEW
9.5.2. COMPANY BASIC INFORMATION
9.5.3. GENERIC DRUGS PRODUCT DETAILS
9.5.4. SANDOZ INTERNATIONAL GMBH GENERIC DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
9.6. DR. REDDY’S LABORATORIES
9.6.1. BUSINESS OVERVIEW
9.6.2. COMPANY BASIC INFORMATION
9.6.3. GENERIC DRUGS PRODUCT DETAILS
9.6.4. DR. REDDY’S LABORATORIES GENERIC DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
9.7. PAR PHARMACEUTICAL, INC.
9.7.1. BUSINESS OVERVIEW
9.7.2. COMPANY BASIC INFORMATION
9.7.3. GENERIC DRUGS PRODUCT DETAILS
9.7.4. PAR PHARMACEUTICAL, INC. GENERIC DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
9.8. APOTEX, INC.
9.8.1. BUSINESS OVERVIEW
9.8.2. COMPANY BASIC INFORMATION
9.8.3. GENERIC DRUGS PRODUCT DETAILS
9.8.4. APOTEX, INC. GENERIC DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
9.9. HOSPIRA, INC.
9.9.1. BUSINESS OVERVIEW
9.9.2. COMPANY BASIC INFORMATION
9.9.3. GENERIC DRUGS PRODUCT DETAILS
9.9.4. HOSPIRA, INC. GENERIC DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
9.10. WATSON PHARMACEUTICALS, LTD.
9.10.1. BUSINESS OVERVIEW
9.10.2. COMPANY BASIC INFORMATION
9.10.3. GENERIC DRUGS PRODUCT DETAILS
9.10.4. WATSON PHARMACEUTICALS, LTD. GENERIC DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
CHAPTER 10. GENERIC DRUGS MARKET VALUE CHAIN ANALYSIS
10.1. GENERIC DRUGS INDUSTRIAL CHAIN ANALYSIS
10.2. GENERIC DRUGS KEY RAW MATERIALS ANALYSIS
10.2.1. KEY RAW MATERIALS
10.2.2. PRICE TREND OF KEY RAW MATERIALS
10.2.3. KEY SUPPLIERS OF RAW MATERIALS
10.3. CONSUMER ANALYSIS
10.3.1. CONSUMER 1
10.3.2. CONSUMER 2
10.3.3. CONSUMER 3
10.3.4. CONSUMER 4